Longitudinal Changes in Relative Market Share Proportions of Biologic, and Targeted Synthetic, Disease-Modifying Anti-Rheumatic Drugs (DMARDs) for Treatment of Rheumatoid Arthritis: Results from the Ontario Best Practices Research Initiative (OBRI)

Authors

Hepworth E; Movahedi M; Rampakakis E; Mirza R; Lau A; Cesta A; Pope J; Sampalis J; Bombardier C

pp. 821-821

J RHEUMATOL PUBL CO

July 1, 2019

Meeting of the Canadian-Rheumatology-Association

CANADA, Montreal

February 27, 2019

March 2, 2019

JOURNAL OF RHEUMATOLOGY

0315-162X

Arthur Lau